Hematology Clinical Trial Expertise

    Millions of people are affected by blood disorders each year.1  Treatments continue to advance in the hematology field with 1,900 clinical trials currently recruiting patients.2  Whether the disease is genetic or acquired, whether it has invaded the blood cells, platelets, bone marrow, vascular endothelium, or plasma proteins, Veristat is equipped to help bring your hematology  therapies to market.

    Hematology Experience

    Veristat has guided clients through the conduct of more than 100 clinical trials and nearly 20 regulatory agency submissions for blood diseases. Our experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic blood disorders and autoimmune blood diseases, as well as blood cancers.
    hematology_experience.png

    Contact Veristat Now

    Request A Proposal

    Contact Us

    Our Malignant & Non-Malignant Blood Disease Expertise

    malignant_blood_disorder_table
    non-malignant_blood_disorder_experience

    FDA Approval - The True Proof of Success

    Veristat supports the first targeted therapy for adult patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 mutation.

    "I have personally had the priviledge to work with a dedicated Agios team on the IND application, phase I study, and NDA submission for ivosidenib. I am thrilled to see TIBSOVO® receive FDA approval and look forward to seeing this therapy help improve the lives of patients with R/R AML."

    Barbara Balser, VMD, Veristat Executive VP & Chief Scientific Officer

    Contact Veristat To Learn More
    hematology_1439x643.png

    To learn more about how we can assist your with your next hematology clinical trial- Contact us or explore more of our hematology resources:

    Contact Us
    Contact Us
    Request A Proposal